LNTH (Lantheus Holdings) Buildings And Improvements : $87 Mil (As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Lantheus Holdings Buildings And Improvements?

Lantheus Holdings's quarterly buildings and improvements increased from Sep. 2024 ($82 Mil) to Dec. 2024 ($86 Mil) and increased from Dec. 2024 ($86 Mil) to Mar. 2025 ($87 Mil).

Lantheus Holdings's annual buildings and improvements declined from Dec. 2022 ($76 Mil) to Dec. 2023 ($73 Mil) but then increased from Dec. 2023 ($73 Mil) to Dec. 2024 ($86 Mil).

Lantheus Holdings Buildings And Improvements Historical Data

The historical data trend for Lantheus Holdings's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantheus Holdings Buildings And Improvements Chart

Lantheus Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Buildings And Improvements

Get a 7-Day Free Trial

70.38

73.56

76.33

73.44

85.52

Lantheus Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Buildings And Improvements	Get a 7-Day Free Trial															73.53	78.04	81.94	85.52	86.92

Lantheus Holdings Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Lantheus Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lantheus Holdings Inc (NAS:LNTH) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

0L8:Germany

Address

201 Burlington Road, South Building, Bedford, MA, USA, 01730

Website

https://www.lantheus.com

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Executives

Marshall Robert J. Jr.	officer: CFO and Treasurer	C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Mary Anne Heino	director, officer: CEO and President	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Paul Blanchfield	officer: Chief Commercial Officer	C/O LANTHEUS HOLDINGS, INC., 331, NORTH BILLERICA MA 01862
James H Thrall	director	343 COMMERCIAL STREET #314, BOSTON MA 02109
Daniel Niedzwiecki	officer: See Remarks	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Gerard Ber	director	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Andrea Sabens	officer: Chief Accounting Officer	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Gary J Pruden	director	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Heinz Christoph Maeusli	director	SCHUETZENWEG 3, ENGELBURG V8 9032
Julie Mchugh	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Sam R Leno	director	C/O BOSTON SCIENTIFIC CORPORATION, ONE BOSTON SCIENTIFIC PLACE, NATICK MA 01760
Minnie Baylor-henry	director	C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Etienne Montagut	officer: See Remarks	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Brian A Markison	director	501 FIFTH STREET, BRISTOL TN 37620
Jean-claude Provost	officer: Chief Medical Officer	C/O LANTHEUS HOLDINGS, INC., 201 BURLINGTON RD, SOUTH BUILDING, BEDFORD MA 01730